

Destruens lung: a rare complication of pulmonary tuberculosis. Case report

Pulmón destruens: una complicación de tuberculosis pulmonar poco habitual. Reporte de un caso

Óscar J. Camacho-Alamo*, Enrique E. Gardea-de la O, and Juan G. Alcaraz-López

Servicio de Neumología, Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jal., Mexico

Abstract

Destruens lung is a rare complication of various nosological entities, with Mycobacterium tuberculosis infection being responsible for 80% of the cases, and it occurs in patients who receive a delayed diagnosis and treatment. The imaging findings observed are a response to compensatory changes in the lung parenchyma, even though adequate management results in various complications following the destruction of the affected lung, which can be fatal in some cases due to the presence of hemoptysis. Likewise, the patient's quality of life is compromised due to being susceptible to opportunistic infections. We present a case of destruens lung secondary to M. tuberculosis infection, which is diagnosed in the context of a major hemoptysis episode.

Keywords: Lung destruens. Destroyed lung. Tuberculosis.

Resumen

El pulmón destruens es una complicación poco frecuente de diversas entidades nosológicas, en el 80% de las cuales la causa de la infección es Mycobacterium tuberculosis; se presenta en pacientes que reciben un diagnóstico y tratamiento retardado. Los hallazgos imagenológicos observados son una respuesta a los cambios compensatorios del parénquima pulmonar, incluso a pesar de un adecuado tratamiento. Las complicaciones tras la destrucción del pulmón afectado son diversas, en algunos casos fatales ante la coinfección por agentes, tanto bacterianos como fúngicos, mismos que pueden perpetuar eventos de hemoptisis; asimismo, la calidad de vida del paciente se ve vulnerada al ser susceptible de infecciones oportunistas. Se presenta un caso de pulmón destruens secundario a infección por M. tuberculosis, que se diagnostica en contexto de episodio de hemoptisis mayor.

Palabras clave: Pulmón destruens. Tuberculosis. Pulmón destruido.

***Correspondence:**

Óscar J. Camacho-Alamo
E-mail: oscar.joseph.08@gmail.com

Date of reception: 12-12-2024
Date of acceptance: 04-03-2025
DOI: 10.24875/NCTE.M25000022

Available online: 12-05-2026
Neumol Cir Torax (Eng). 2025;84(2):146-150
www.revistanct.org.mx

2594-1526 / © 2025 Sociedad Mexicana de Neumología y Cirugía de Tórax. Publicado por Permanyer. Este es un artículo open access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Destroyed lung (destruens lung) is a rare complication of several disease entities, most frequently secondary to *Mycobacterium tuberculosis* infection, which accounts for approximately 80% of cases. It typically occurs in patients with delayed diagnosis and treatment. The imaging findings reflect compensatory changes in the remaining pulmonary parenchyma. Despite adequate antituberculous therapy, complications following destruction of the affected lung are diverse and may be fatal, particularly in the presence of hemoptysis. Additionally, patients experience impaired quality of life due to increased susceptibility to opportunistic infections. We report a case of destroyed lung due to *M. tuberculosis* infection, diagnosed in the context of a major hemoptysis episode.

Case presentation

A 27-year-old woman from Tepatitlán, Jalisco, Mexico, homemaker, single, from a low socioeconomic background, with a maternal family history of breast cancer, presented for evaluation. She had no relevant environmental exposures. She reported contact with a chronic cough (father), although the cause was unknown. Since childhood, she had experienced chronic cough and had been treated since 2007 as having asthma without spirometric confirmation, using short-acting bronchodilators as needed. In October 2019, she sought medical attention for weight loss and productive cough. Chest radiography revealed a cavitory lesion in the left pulmonary apex. Serial sputum acid-fast bacilli smears were positive. She was diagnosed with cavitory pulmonary tuberculosis and received isoniazid, rifampin, pyrazinamide, and ethambutol for 60 doses, followed by rifampin and isoniazid for 45 doses. Sputum cultures at the end of therapy were negative, and she was declared cured in April 2020.

The patient continued to have a nonproductive cough after completing antituberculous therapy. In March 2023, she developed low-grade fever, followed in April 2023 by hemoptysis quantified at approximately 500 mL. On physical examination, she was underweight. The chest was asymmetric, with absent vocal fremitus and hyperresonance over the left hemithorax, and decreased breath sounds consistent with a rarefaction syndrome. Laboratory testing showed hemoglobin 9 g/dL, hematocrit 28%, platelets $202 \times 10^3/\mu\text{L}$, leukocytes $6.72 \times 10^3/\mu\text{L}$, neutrophils 58%, and glucose 102 mg/dL. Chest computed tomography (CT) in lung window demonstrated

anterior herniation of the right lung, mediastinal traction toward the left, narrowing of the intercostal spaces, and areas of decreased attenuation following bronchial pathways suggestive of cystic bronchiectasis (Figure 1).

Bronchoscopy revealed concentric narrowing of the middle third of the left main bronchus, preventing passage of the bronchoscope, suggestive of extrinsic compression vs external scarring without evidence of endobronchial infiltration. Bronchoalveolar lavage RT-PCR for tuberculosis and mycobacterial culture were negative. Fungal culture yielded *Aspergillus nidulans* (Figure 2). The patient received itraconazole 200 mg twice daily with favorable clinical response. Due to the risk of recurrent bleeding and bronchiectasis colonization, she was evaluated by thoracic surgery and considered a candidate for left pneumonectomy, pending pulmonary function assessment and nutritional optimization.

Discussion

Tuberculosis is an infectious disease caused by *Mycobacterium tuberculosis*. This pathogen produces a broad spectrum of disease involving both pulmonary and extrapulmonary sites¹. According to the 2021 World Health Organization (WHO) report, approximately 25% of the global population has immunologic evidence of prior infection with *M. tuberculosis*. In Mexico, according to the 2022 national tuberculosis surveillance report, 78.7% of cases involved pulmonary disease, followed by miliary tuberculosis (4.7%) and lymph node involvement (4.6%). Mortality data indicate that up to 1.4 million deaths were attributed to this pathogen in 2020, making it the 2nd leading infectious cause of death worldwide that year, after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)².

The clinical spectrum of tuberculosis depends largely on host susceptibility, with increased risk observed in individuals with diabetes mellitus, alcohol use disorder, or HIV infection. Pulmonary tuberculosis is classically categorized into 3 forms³ (Table 1).

In recent years, the concept of post-tuberculosis disease has gained increasing attention because of the long-term sequelae that may persist despite appropriate antimicrobial treatment. Post-tuberculosis disease is defined as chronic respiratory abnormalities, with or without associated symptoms, attributable to prior pulmonary tuberculosis. Its reported prevalence varies widely, ranging from 18% to 87%, reflecting the lack of standardized definitions and limited epidemiologic data¹. Destroyed lung (pulmón destruido) is included within this spectrum of post-tuberculosis sequelae.




Figure 1. **A:** axial chest CT in mediastinal window showing mediastinal shift to the left and rib crowding. **B y C:** axial lung window CT images demonstrating pulmonary parenchymal herniation and mediastinal displacement with areas of increased attenuation containing regions of decreased attenuation suggestive of bronchiectasis. **D:** coronal lung window image showing absence of pulmonary parenchyma in the left hemithorax, elevation of the ipsilateral hemidiaphragm, and cystic and varicose bronchiectasis.

Destroyed lung is defined as a combination of parenchymal and pleural destruction manifested radiologically by cavitation, bronchiectasis, loss of lung volume, and mediastinal shift toward the affected side⁵. It is more frequently reported in countries with limited health care resources. The principal cause is *M. tuberculosis* infection (approximately 80% of cases), followed by necrotizing pneumonia and advanced stages of bronchiectasis⁶. This complication develops in approximately 1.3% of patients despite appropriate antituberculous treatment⁷.

Risk factors identified in case series include male sex, a mean age at presentation of approximately 55 years, and a history of tuberculosis diagnosed during childhood or adolescence⁵. Patients are often initially asymptomatic and later develop chronic symptoms, including productive cough (occasionally purulent), hemoptysis, fever, and dyspnea. Physical examination may reveal thoracic asymmetry on the affected side, with decreased and horizontally oriented intercostal

spaces⁸. On posteroanterior chest radiography, findings may include diffuse opacification of the affected hemithorax, ipsilateral mediastinal deviation, cystic bronchiectasis, and cavitation. On lateral projection, retrosternal hyperlucency may be observed, consistent with compensatory hyperinflation of the contralateral lung⁹.

Computed tomography findings described by Shital et al are summarized in figure 3¹⁰. Case series have reported left lung predominance in approximately 58.1% of cases. Anterior herniation of the contralateral lung into the mediastinum, involving the upper and middle lobes, occurs in 92% of cases; posterior herniation involving the lower lobe occurs in 85%; and simultaneous anterior and posterior herniation occurs in 77%^{5,11}. The higher frequency of left-sided involvement is attributed to bronchial anatomy, as the left main bronchus is longer, narrower, and more horizontally oriented than the right, which impairs secretion drainage¹².

Table 1. Pathologic forms of pulmonary infection due to *Mycobacterium tuberculosis* and their imaging signs

Primary	Consolidation, predominantly in the upper lobes; pleural effusion; miliary pattern; hilar and mediastinal lymphadenopathy
Postprimary (reactivation)	Cavitary and/or nodular disease
Latent	Positive tuberculin skin test or molecular testing without imaging or clinical findings suggestive of primary or postprimary tuberculosis




Figure 2. Isolation of *Aspergillus nidulans* with Hülle cells on lactophenol cotton blue stain.

Surgical management is reserved for patients with complications such as massive hemoptysis, bronchopleural fistula, or empyema. Described procedures include pneumonectomy, pleuropneumonectomy, and bronchopleural fistula repair combined with pneumonectomy. The specific indication for each procedure remains controversial, and no clear consensus exists. In a case series of 172 patients, pleuropneumonectomy was performed in those with destroyed lung and pleural adhesions; pneumonectomy was preferred in the absence of empyema or bronchopleural fistula; and combined bronchopleural fistula repair with pneumonectomy was selected when fistula was present¹³. The overall operative mortality for pneumonectomy has been reported at approximately 4%. The most common postoperative complications include bronchopleural fistula (12%) and empyema (32%). Absolute contraindications include forced expiratory volume in 1 second (FEV₁) < 2 L and diffusion capacity of the lung for carbon monoxide < 60% predicted.

Coinfection has been described in small case series in up to 46.1% of patients, most commonly involving gram-negative organisms such as *Pseudomonas aeruginosa* and *Haemophilus influenzae*, and less frequently fungal infections¹⁴.

Conclusions

Destroyed lung is a rare but severe complication of *M. tuberculosis* infection. Although early and appropriate




Figure 3. Tomographic findings of destroyed lung.

antituberculous therapy reduces its incidence, characteristic imaging findings allow diagnosis when it occurs. Management recommendations continue to evolve.

Funding

This study received no specific funding from public, commercial, or nonprofit agencies.

Conflicts of interest

The authors declared no conflicts of interest whatsoever.

Ethical considerations

Protection of humans and animals. No experiments were performed in humans or animals.

Confidentiality and informed consent. The study does not involve identifiable patient data and did not require ethics committee approval. SAGER guidelines: Not applicable.

Declaration on the use of artificial intelligence. The authors declare that no generative artificial intelligence was used in the preparation of this manuscript.

References

- Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. *Nat Rev Dis Primers*. 2016;2:16076. <https://doi.org/10.1038/nrdp.2016.76>.
- Secretaría de Salud, Centro Nacional de Programa Preventivos y Control de Enfermedades. Sistema Integral de Vigilancia Epidemiológica de TB. Situación Epidemiológica México [Internet]. México: Secretaría de Salud, Centro Nacional de Programa Preventivos y Control de Enfermedades; 14/02/2022. Available from: https://www.gob.mx/cms/uploads/attachment/file/722796/1.-SITUACION_EPIDEMIOLOGICA_GICA_2021_preliminar.pdf.
- Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am J Respir Crit Care Med*. 2000;161(4 Pt 1):1376-95. <https://doi.org/10.1164/ajrccm.161.4.16141>.
- Silva DR, Santos AP, Visca D, Bombarda S, Dalcolmo MMP, Galvão T, et al. Brazilian Thoracic Association recommendations for the management of post-tuberculosis lung disease. *J Bras Pneumol*. 2024;49(6):e20230269. <https://doi.org/10.36416/1806-3756/e20230269>.
- Varona Porres D, Persiva O, Pallisa E, Andreu J. Radiological findings of unilateral tuberculous lung destruction. *Insights Imaging*. 2017;8(2):271-7. <https://doi.org/10.1007/s13244-017-0547-4>.
- Kao B, Riquet M, Bellamy J, Debesse B. Les poumons détruits. A propos de 46 malades opérés [The destroyed lung. Apropos of 46 surgical patients]. *Rev Pneumol Clin*. 1989;45(6):237-42.
- Issoufou I, Sani R, Belliraj L, Ammor FZ, Moussa Ounteini A, Ghalimi J, et al. Pneumonectomie pour poumon détruit post-tuberculeux: une série de 26 cas opérés [Pneumectomy for tuberculosis destroyed lung: A series of 26 operated cases]. *Rev Pneumol Clin*. 2016;72(5):288-92. <https://doi.org/10.1016/j.pneumo.2016.07.001>.
- Bai L, Hong Z, Gong C, Yan D, Liang Z. Surgical treatment efficacy in 172 cases of tuberculosis-destroyed lungs. *Eur J Cardiothorac Surg*. 2012;41(2):335-40. <https://doi.org/10.1016/j.ejcts.2011.05.028>.
- Kim HY, Song KS, Goo JM, Lee JS, Lee KS, Lim TH. Thoracic sequelae and complications of tuberculosis. *Radiographics*. 2001;21(4):839-60; discussion 859-60. <https://doi.org/10.1148/radiographics.21.4.g01j106839>.
- Patil S, Narkar S, Raka V, Dahiphale J, Choudhari S, Gondhali G. 'Destroyed lung' as post tuberculosis sequel: A preventable stigma of 'disease of concern' of Millennium! *Saudi J Med*. 2023;8(3):112-9. DOI: 10.36348/sjm.2023.v08i03.007.
- Fawibe AE, Salami AK, Oluboyo PO, Desalu OO, Odeigha LO. Profile and outcome of unilateral tuberculous lung destruction in Ilorin, Nigeria. *West Afr J Med*. 2011;30(2):130-5.
- Moreno MN, Miguel DJ, González CG. Monografías NeumoMadrid. En: Simón Adiego C, García Luján R. Volumen XVI. Cirugía en patología pulmonar no tumoral. Madrid: Ergon; 2010: pp. 23-43.
- Li Y, Hu X, Jiang G, Chen C. Pneumectomy for treatment of destroyed lung: a retrospective study of 137 patients. *Thorac Cardiovasc Surg*. 2017;65(7):528-34. <https://doi.org/10.1055/s-0036-1583524>.
- Pomerantz BJ, Cleveland JC Jr, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. *J Thorac Cardiovasc Surg*. 2001;121(3):448-53. <https://doi.org/10.1067/mtc.2001.112339>.